Around 97% of patients with advanced pancreatic cancer die within five years. Researchers have figured out a way to target ...
For decades, pancreatic cancer has been one of the most lethal cancers, with few effective treatment options. A new drug, daraxonrasib, targets the KRAS mutation that fuels most pancreatic ...
"One of the most amazing things I’ve ever seen," clinician-scientist Samuel Hume wrote alongside a video clip posted on X.
A phase 3 clinical trial has demonstrated that daraxonrasib significantly improved overall survival and progression-free ...
Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) (Actinium or the Company), a pioneer in the development of targeted ...
The landmark success of a drug against an ‘undruggable’ cancer is spurring fresh optimism in the quest to treat seemingly ...
Morning Overview on MSN
A single oral pill just pushed RAS-mutant lung cancer tumor response rates past 74% in first-line patients — KRAS inhibitor olomorasib cleared for pivotal read at ASCO
For patients diagnosed with advanced lung cancer driven by a specific genetic flaw called KRAS G12C, the first-line treatment ...
Discussion highlights growing importance on novel ADC payloads, and Akari’s ASCO data in KRAS-driven cancers and future ...
A new era in the treatment of deadly pancreatic cancer was heralded by scientists this week, thanks to science by the ...
FDA grants Fast Track designation to VS-7375, an oral investigational KRAS G12D inhibitor, for locally advanced or metastatic ...
Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results